MRNA-4157/V940 a personalised MRNA cancer vaccine + Keytruda met primary efficacy endpoint in phase IIB KEYNOTE 942 trial to treat melanoma
Moderna, Inc.and Merck Inc., announced that the Phase IIb KEYNOTE-942/mRNA-4157-P201 trial of mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with Keytruda, Merck's anti-PD-1 therapy, demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of recurrence-free survival (RFS) versus Keytruda alone for the adjuvant treatment of patients with stage III/IV melanoma following complete resection